NEW EVENT THIS THURSDAY! New drug for HER2+ Breast Cancer

FDA Approved for Adult Patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting! Learn more!

See program details below! Grab a seat!

Invitation - ENHERTU Extending HER2+ Expectations (REF# 6101535 5497606)

.pdf

Download PDF • 3.04MB